Value
3.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 3.0 |
- ▸Expensive valuation
PLSE · Why this verdict
Why Pulse Biosciences (PLSE) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.1/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Pulse Biosciences burns free cash flow at -3,872% of revenue, meaning for every dollar of revenue generated the company spends nearly 39 dollars in cash — an extreme pre-commercialization burn rate indicating the company has not yet demonstrated a viable business model. Quality breakdown | Free cash flow burn rate improves to below -500% of revenue within 12 months as commercial product revenue begins to scale meaningfully. | →Stable |
| CounterFor early-stage medical device companies with novel technology platforms, extreme burn rates relative to current revenue are expected and normal — the relevant metric is cash runway, not current burn rate. | ||
Short interest of 16% of float — the highest in this batch of analyzed companies — combined with implied volatility of 149% indicates significant market skepticism about the company's near-term prospects and creates a high-cost-of-capital environment for potential short squeeze scenarios. Key risks | Short interest falls below 10% within 12 months as commercial milestones reduce uncertainty and bear thesis holders cover positions. | →Stable |
| CounterHigh short interest in development-stage medical device companies is common and can reverse rapidly on positive clinical data or regulatory approval milestones, which are binary outcome events. | ||
Pulse Biosciences has split 2 beats and 2 misses in the last 4 quarters with a barely positive average surprise of 0.8%, and the most recent quarter was a miss at -9.7% (actual -$0.24 versus estimate -$0.22), showing no consistent pattern of outperforming expectations. Earnings | The company beats consensus loss estimates in the next 2 consecutive quarterly reports, demonstrating improving cost control. | →Stable |
| CounterIn development-stage companies, EPS beats on loss quarters often reflect one-time cost cuts or timing of R&D spend rather than fundamental improvement in the commercial trajectory. | ||
With a take-profit price target of $26.07 against a current price of $25.93, the implied upside is only 0.5% while the downside stop-loss at $24.11 represents a 7% loss — a risk/reward ratio of 0.09 that makes any long position nearly irrational from a position-sizing perspective. Targets | Analyst price targets are revised above $35, representing more than 35% upside from current levels, within 12 months following a significant commercial catalyst. | →Stable |
| CounterCurrent analyst targets may be lagging indicators for a pre-commercial company where a single regulatory or partnership announcement could render the price target stale within days. | ||
Pulse Biosciences burns free cash flow at -3,872% of revenue, meaning for every dollar of revenue generated the company spends nearly 39 dollars in cash — an extreme pre-commercialization burn rate indicating the company has not yet demonstrated a viable business model.
→StableQuality breakdown
- Expectation
- Free cash flow burn rate improves to below -500% of revenue within 12 months as commercial product revenue begins to scale meaningfully.
CounterFor early-stage medical device companies with novel technology platforms, extreme burn rates relative to current revenue are expected and normal — the relevant metric is cash runway, not current burn rate.
Short interest of 16% of float — the highest in this batch of analyzed companies — combined with implied volatility of 149% indicates significant market skepticism about the company's near-term prospects and creates a high-cost-of-capital environment for potential short squeeze scenarios.
→StableKey risks
- Expectation
- Short interest falls below 10% within 12 months as commercial milestones reduce uncertainty and bear thesis holders cover positions.
CounterHigh short interest in development-stage medical device companies is common and can reverse rapidly on positive clinical data or regulatory approval milestones, which are binary outcome events.
Pulse Biosciences has split 2 beats and 2 misses in the last 4 quarters with a barely positive average surprise of 0.8%, and the most recent quarter was a miss at -9.7% (actual -$0.24 versus estimate -$0.22), showing no consistent pattern of outperforming expectations.
→StableEarnings
- Expectation
- The company beats consensus loss estimates in the next 2 consecutive quarterly reports, demonstrating improving cost control.
CounterIn development-stage companies, EPS beats on loss quarters often reflect one-time cost cuts or timing of R&D spend rather than fundamental improvement in the commercial trajectory.
With a take-profit price target of $26.07 against a current price of $25.93, the implied upside is only 0.5% while the downside stop-loss at $24.11 represents a 7% loss — a risk/reward ratio of 0.09 that makes any long position nearly irrational from a position-sizing perspective.
→StableTargets
- Expectation
- Analyst price targets are revised above $35, representing more than 35% upside from current levels, within 12 months following a significant commercial catalyst.
CounterCurrent analyst targets may be lagging indicators for a pre-commercial company where a single regulatory or partnership announcement could render the price target stale within days.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Pulse Biosciences is a pre-revenue-stage medical device company with a quality score of 2.1 out of 10, free cash flow burn of -3872% of revenue, and only 0.5% implied price upside — making it an unattractive investment with no risk-reward justification at current levels near $25.93.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
2.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.7 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -3872% of revenue
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.3 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 0.3 |
- ▸Overbought (RSI 73)
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 5.8 |
| erm sentiment | 4.7 |
Insider
7.4/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 9.0 |
| insider conviction | 8.0 |
| holder change | 5.1 |
- ▸Heavy insider buying — $26,590,676 (1.316% of mkt cap)
Peer rank
2.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.3 |
| growth rank | 5.0 |
Technical
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.0 |
| support resistance | 2.8 |
| 52w position | 8.8 |
Risk (lower is worse)
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 2.7 |
| days to cover | 1.5 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 4.5 |
| debt equity | 9.6 |
- ▸High IV: 101%
- ▸Above max pain $3
Catalyst
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 2.9 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:4.9>=4.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:40d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.7=NEGATIVE
Warning (1)
- MOMENTUM:4.9<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
-0.70
Upside
-10.5%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — Beta 1.65>1.3, MCap $2.0B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Insider at 7.4 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-0.7=NEGATIVE.
The strongest dimensions are Insider at 7.4, Sentiment at 5.2, and Growth at 5.0; the weakest are Quality at 2.1, Peer rank at 2.6, and Value at 3.0. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -0.70 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Extreme Cash Burn Rate
Trip ifCash burn rate remains above -1000% of revenue for 4 consecutive quarters with no evidence of commercialization progress.
- P2High Short Interest Signal
Trip ifShort interest rises above 20% of float, indicating further deterioration in institutional confidence.
- P3Mixed Earnings Track Record
Trip ifEarnings miss consensus estimates by more than 15% in 2 of the next 3 quarterly reports.
- P4Near Zero Price Upside
Trip ifStock price drops below $22, exceeding a 15% decline from current levels with no corresponding catalyst announcement.